Home / Share Price Target / Pdpl
Parenteral Drugs Share Price Target 2024, 2025, 2026 to 2039 With Charts
Parenteral Drugs | |||
 | Symbol: PDPL | ||
| Price: ₹2.9 | |||
| Exchange: NSE | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Parenteral Drugs Brief Company Overview
- 1.1: Company Overview: Parenteral Drugs (India) Limited
- 1.2: Parenteral Drugs Financial Performance
- 1.2.1: Is Parenteral Drugs A Good Buy For Long Term?
- 2: Approach 1: Technical Analysis Paired With Price Action
- 2.1: Parenteral Drugs Share Price Target For 2024
- 2.1.1: Parenteral Drugs Share Price Target Table For 2024
- 2.1.2: Summary: Parenteral Drugs Share Price Prediction For 2024
- 2.2: Parenteral Drugs Share Price Target For 2025
- 2.2.1: Parenteral Drugs Share Price Target Table For 2025
- 2.2.2: Summary: Parenteral Drugs Share Price Prediction For 2025
- 3: Approach 2: Machine Learning By Studying Historical Prices
- 3.1: Parenteral Drugs Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 3.2: Parenteral Drugs Share Price Target Table From 2024, 2025, 2026 to 2039
- 4: Parenteral Drugs Past Performance
Parenteral Drugs Brief Company Overview
Company Overview: Parenteral Drugs (India) Limited
Incorporated in 1983 and headquartered in Indore, India, Parenteral Drugs (India) Limited is a prominent healthcare company renowned for its extensive range of pharmaceutical products.
Their diverse product portfolio includes:
- Intravenous infusion
- Inhalation products
- Veterinary infusion
- IV fluids (carbohydrates, electrolytes, diuretics, dialysis and irrigation solutions)
- Anti-infective and anti-fungal products
- Oncology and anaesthesia products
Parenteral Drugs (India) Limited has a strong market presence, not only in India but also globally, with exports reaching countries such as Iraq, Yemen, Mozambique, Ghana, Kenya, Vietnam, and Myanmar, among others.
The company is committed to providing high-quality healthcare products and services, adhering to stringent industry standards.
Advertisement
Parenteral Drugs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 10.1 Crore | Market valuation of Parenteral Drugs's shares. |
| Revenue (TTM) | 8.49 Crore | Total revenue generated by Parenteral Drugs over the past twelve months. |
| Net Income (TTM) | -76.36 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -1863.35% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 35.67% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) | -31% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio | 3.59 | Company's total debt divided by total shareholder equity. |
| Total Debt | 107.19 Crore | Sum of Parenteral Drugs's current & long-term financial obligations. |
| Total Cash | 1,000 | Total amount of liquid funds available to Parenteral Drugs. |
| Beta | 0.18 | Beta is less than 1 indicating that the Parenteral Drugs's price is less volatile than the market. |
Is Parenteral Drugs A Good Buy For Long Term?
Parenteral Drugs, with a small market cap and significant debt, presents a risky investment opportunity. Its revenue decline and negative profit margin indicate financial challenges. While it has experienced positive returns over the past three years, it has underperformed over the past five years. Based on this data, it is not a recommended buy for long-term investment.
To predict the Parenteral Drugs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Parenteral Drugs Share Price Target For 2024
The line chart displays the monthly closing prices of Parenteral Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Parenteral Drugs shares in 2024, see the table below.
Advertisement
Parenteral Drugs Share Price Target Table For 2024
| Parenteral Drugs's Levels | Value | Reason/Importance |
|---|---|---|
| 2024 Target 3 | 3.00 (+3.44%) | Price Action: Sep 2022 Low |
| 2024 Target 2 | 2.93 (+1.03%) | Price Action: Chart |
| 2024 Target 1 | 2.90 (0%) | Fibonacci Extension Level 199% |
| Current Price | 2.90 | Parenteral Drugs's 1 share price as of Thu 05 Sep 2024 |
| Stop Loss 1 | 2.90 (0%) | Fibonacci Retracement Extended 82.6% |
| Stop Loss 2 | 2.85 (-1.73%) | Price Action: Sep 2021 Low |
| Stop Loss 3 | 2.80 (-3.45%) | Price Action: Jun 2022 Low |
Summary: Parenteral Drugs Share Price Prediction For 2024
In summary, Parenteral Drugs has surged by ₹0.00, achieving a notable +0.00% increase from 1st January 2024 to 05 Sep 2024. Despite the setback, our analysis of Parenteral Drugs for 2024 predicts an additional rise of 0% to 3.44% by the end of 2024 with three potential targets T1: 2.90, T2: 2.93, T3: 3.00. Stop Loss at SL1: 2.90, SL2: 2.85, SL3: 2.80.
Parenteral Drugs has a 52-week high of ₹2.90, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹2.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Parenteral Drugs.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Parenteral Drugs Share Price Target For 2025
The line chart displays the monthly closing prices of Parenteral Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Parenteral Drugs shares in 2025, see the table below.
Advertisement
Parenteral Drugs Share Price Target Table For 2025
| Parenteral Drugs's Levels | Value | Reason/Importance |
|---|---|---|
| 2025 Target 3 | 3.39 (+16.89%) | Custom Fibonacci Extension Lvl 82% |
| 2025 Target 2 | 3.32 (+14.48%) | Price Action: Chart |
| 2025 Target 1 | 3.29 (+13.44%) | Custom Fibonacci Extension Lvl 64.9% |
| Current Price | 2.90 | Parenteral Drugs's 1 share price as of Thu 05 Sep 2024 |
| Stop Loss 1 | 2.80 (-3.45%) | Price Action: Jun 2022 Low |
| Stop Loss 2 | 2.75 (-5.18%) | Price Action: Nov 2019 High |
| Stop Loss 3 | 2.70 (-6.9%) | Price Action: Aug 2023 Low |
Summary: Parenteral Drugs Share Price Prediction For 2025
In summary, Parenteral Drugs has surged by ₹0.00, achieving a notable +0.00% increase from 1st January 2024 to 05 Sep 2024. Despite the setback, our analysis of Parenteral Drugs for 2025 predicts an additional rise of 13.44% to 16.89% by the end of 2025 with three potential targets T1: 3.29, T2: 3.32, T3: 3.39. Stop Loss at SL1: 2.80, SL2: 2.75, SL3: 2.70.
Parenteral Drugs has a All-Time high of ₹400.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹2.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Parenteral Drugs, we have created a specific page for that check here: Parenteral Drugs Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Parenteral Drugs Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
This chart presents a detailed projection of Parenteral Drugs share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 7.06% over the next 15 years.
For complete year by year Parenteral Drugs long term share price target from 2024, 2025 to 2039 check the below table.
Parenteral Drugs Share Price Target Table From 2024, 2025, 2026 to 2039
| Year | Parenteral Drugs Target | YoY Change % |
|---|---|---|
| 2024 | ₹2.9 | [Current Price] |
| 2024 | ₹3.46 | 19.31% |
| 2025 | ₹3.46 | 0% |
| 2026 | ₹3.81 | 10.11% |
| 2027 | ₹4.34 | 13.91% |
| 2028 | ₹5.66 | 30.41% |
| 2029 | ₹5.74 | 1.41% |
| 2030 | ₹5.47 | -4.71% |
| 2031 | ₹5.79 | 5.85% |
| 2032 | ₹6.39 | 10.36% |
| 2033 | ₹8.11 | 26.91% |
| 2034 | ₹8.02 | -1.11% |
| 2035 | ₹7.48 | -6.74% |
| 2036 | ₹7.78 | 4.01% |
| 2037 | ₹8.43 | 8.35% |
| 2038 | ₹10.55 | 25.14% |
| 2039 | ₹8.99 | -14.79% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Parenteral Drugs Past Performance
- In 2010, Parenteral Drugs opening price was ₹195.08
- As of Thu 05 Sep 2024 the price stands at ₹2.9.
- This represents a Compound Annual Growth Rate (CAGR) of -24.47%.
- In 14 years, an investment of 10,000 would have become ₹148.65.
As we wrap up, we hope you like our study on Parenteral Drugs share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.
